{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:37:33Z","timestamp":1793489853526,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803645"],"award-info":[{"award-number":["81803645"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Letters"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.toxlet.2021.04.016","type":"journal-article","created":{"date-parts":[[2021,4,24]],"date-time":"2021-04-24T02:29:03Z","timestamp":1619231343000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["PXR-mediated expression of FABP4 promotes valproate-induced lipid accumulation in HepG2 cells"],"prefix":"10.1016","volume":"346","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5867-8039","authenticated-orcid":false,"given":"Liang","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinfei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lirong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.toxlet.2021.04.016_bib0005","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.bcp.2009.10.011","article-title":"Inhibition of hepatic carnitine palmitoyl-transferase I (CPT IA) by valproyl-CoA as a possible mechanism of valproate-induced steatosis","volume":"79","author":"Aires","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0010","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.atherosclerosis.2016.04.012","article-title":"Exogenous FABP4 induces endoplasmic reticulum stress in HepG2 liver cells","volume":"249","author":"Bosquet","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.toxlet.2021.04.016_bib0015","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbagrm.2016.03.002","article-title":"Nuclear receptors and nonalcoholic fatty liver disease","volume":"1859","author":"Cave","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.toxlet.2021.04.016_bib0020","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1124\/dmd.106.014456","article-title":"Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways","volume":"35","author":"Cerveny","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0025","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9576503","article-title":"Study of valproic acid-enhanced hepatocyte steatosis","volume":"2016","author":"Chang","year":"2016","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0030","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1101\/gr.246900.118","article-title":"Targeted delivery of CRISPR interference system against Fabp4 to white adipocytes ameliorates obesity, inflammation, hepatic steatosis, and insulin resistance","volume":"29","author":"Chung","year":"2019","journal-title":"Genome Res."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0035","doi-asserted-by":"crossref","first-page":"19785","DOI":"10.1038\/s41598-019-56235-y","article-title":"FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis","volume":"9","author":"Coilly","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0040","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.bbagrm.2016.02.008","article-title":"A SUMO-acetyl switch in PXR biology","volume":"1859","author":"Cui","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.toxlet.2021.04.016_bib0045","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.3390\/cells9112395","article-title":"Regulation of CAR and PXR expression in health and disease","volume":"9","author":"Daujat-Chavanieu","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.toxlet.2021.04.016_bib0050","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cbi.2009.07.019","article-title":"Cytometric analysis for drug-induced steatosis in HepG2 cells","volume":"181","author":"Donato","year":"2009","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.cell.2014.03.012","article-title":"Nuclear receptors, RXR, and the big bang","volume":"157","author":"Evans","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.toxlet.2021.04.016_bib0060","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/sj.bjp.0706830","article-title":"The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver","volume":"149","author":"Eyal","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd2589","article-title":"Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets","volume":"7","author":"Furuhashi","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0070","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cbi.2006.11.004","article-title":"A human hepatocellular in vitro model to investigate steatosis","volume":"165","author":"G\u00f3mez-Lech\u00f3n","year":"2007","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0075","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/1381612825666190329145428","article-title":"Valproic acid and the liver injury in patients with epilepsy: an update","volume":"25","author":"Guo","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0080","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jhep.2018.12.038","article-title":"Non-nucleoside reverse transcriptase inhibitor efavirenz activates PXR to induce hypercholesterolemia and hepatic steatosis","volume":"70","author":"Gwag","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0085","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.bbagrm.2016.03.012","article-title":"Regulation of hepatic energy metabolism by the nuclear receptor PXR","volume":"1859","author":"Hakkola","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.toxlet.2021.04.016_bib0090","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1210\/er.2001-0038","article-title":"The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism","volume":"23","author":"Kliewer","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0095","doi-asserted-by":"crossref","first-page":"341","DOI":"10.2174\/1389200211314030009","article-title":"Pregnane X receptor (PXR) at the crossroads of human metabolism and disease","volume":"14","author":"Koutsounas","year":"2013","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0100","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/j.gastro.2004.04.019","article-title":"Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes","volume":"127","author":"Langmann","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.toxlet.2021.04.016_bib0105","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1124\/mol.114.097287","article-title":"SLC13A5 is a novel transcriptional target of the pregnane X receptor and sensitizes drug-induced steatosis in human liver","volume":"87","author":"Li","year":"2015","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eplepsyres.2009.04.004","article-title":"Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment","volume":"86","author":"Luef","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0115","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/jcp.24838","article-title":"Pregnane X receptor as the \u201csensor and effector\u201d in regulating epigenome","volume":"230","author":"Ma","year":"2015","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0120","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2013.06.012","article-title":"Adverse drug reactions induced by valproic acid","volume":"46","author":"Nanau","year":"2013","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0125","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1006\/bbrc.1999.1071","article-title":"PPARgamma activation induces the expression of the adipocyte fatty acid binding protein gene in human monocytes","volume":"261","author":"Pelton","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0130","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2165\/00023210-200216100-00004","article-title":"Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience","volume":"16","author":"Perucca","year":"2002","journal-title":"CNS Drugs"},{"key":"10.1016\/j.toxlet.2021.04.016_bib0135","doi-asserted-by":"crossref","first-page":"36734","DOI":"10.1074\/jbc.M101287200","article-title":"Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen","volume":"276","author":"Phiel","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0140","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3923\/pjbs.2012.68.77","article-title":"Non alcoholic fatty liver disease, insulin resistance, dyslipidemia and atherogenic ratios in epileptic children and adolescents on long term antiepileptic drug therapy","volume":"15","author":"Saleh","year":"2012","journal-title":"Pak. J. Biol. Sci."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0145","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review","volume":"31","author":"Silva","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0150","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2174\/1389200214666131211153307","article-title":"Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily","volume":"14","author":"Smutny","year":"2013","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0155","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.apsb.2019.09.010","article-title":"The 3\u2019-untranslated region contributes to the pregnane X receptor (PXR) expression down-regulation by PXR ligands and up-regulation by glucocorticoids","volume":"10","author":"Smutny","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.toxlet.2021.04.016_bib0160","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/liv.13639","article-title":"Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma","volume":"38","author":"Thompson","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0165","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.2337\/dc07-0413","article-title":"Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort","volume":"30","author":"Tso","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.toxlet.2021.04.016_bib0170","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.tox.2017.11.013","article-title":"Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction","volume":"393","author":"van Breda","year":"2018","journal-title":"Toxicology"},{"key":"10.1016\/j.toxlet.2021.04.016_bib0175","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/2042018818759894","article-title":"9- and 13-HODE regulate fatty acid binding protein-4 in human macrophages, but does not involve HODE\/GPR132 axis in PPAR-gamma regulation of FABP4","volume":"9","author":"Vangaveti","year":"2018","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0180","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/jpet.118.252940","article-title":"The HNF1alpha-regulated LncRNA HNF1alpha-AS1 is involved in the regulation of cytochrome P450 expression in human liver tissues and Huh7 cells","volume":"368","author":"Wang","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2020.104797","article-title":"Epigenetic toxicity of PFOA and GenX in HepG2 cells and their role in lipid metabolism","volume":"65","author":"Wen","year":"2020","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.toxlet.2021.04.016_bib0190","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1373\/clinchem.2005.062463","article-title":"Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome","volume":"52","author":"Xu","year":"2006","journal-title":"Clin. Chem."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0195","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.placenta.2016.08.086","article-title":"Modulation of FABP4 hypomethylation by DNMT1 and its inverse interaction with miR-148a\/152 in the placenta of preeclamptic rats and HTR-8 cells","volume":"46","author":"Yang","year":"2016","journal-title":"Placenta"},{"key":"10.1016\/j.toxlet.2021.04.016_bib0200","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1161\/ATVBAHA.107.146274","article-title":"Serum adipocyte fatty acid-binding protein levels were independently associated with carotid atherosclerosis","volume":"27","author":"Yeung","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0205","article-title":"microRNA-211 promotes invasion and migration of colorectal cancer cells by targeting FABP4 via PPARgamma","author":"Zhao","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0210","doi-asserted-by":"crossref","first-page":"15013","DOI":"10.1074\/jbc.M511116200","article-title":"A novel pregnane X receptor-mediated and sterol regulatory element-binding protein-independent lipogenic pathway","volume":"281","author":"Zhou","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.toxlet.2021.04.016_bib0215","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2007.11.037","article-title":"Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis","volume":"134","author":"Zhou","year":"2008","journal-title":"Gastroenterology"}],"container-title":["Toxicology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427421001090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378427421001090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:53:42Z","timestamp":1777568022000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378427421001090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":43,"alternative-id":["S0378427421001090"],"URL":"https:\/\/doi.org\/10.1016\/j.toxlet.2021.04.016","relation":{},"ISSN":["0378-4274"],"issn-type":[{"value":"0378-4274","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PXR-mediated expression of FABP4 promotes valproate-induced lipid accumulation in HepG2 cells","name":"articletitle","label":"Article Title"},{"value":"Toxicology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxlet.2021.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}